JAC Advance Access originally published online on March 24, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 696-699
© 2004 The British Society for Antimicrobial Chemotherapy
Leading Article |
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy
1 The Epidemiology and Prevention Interventions Center, San Francisco General Hospital, UCSF; 2 The San Francisco General Hospital AIDS Program, UCSF; 3 The Department of Epidemiology and Biostatistics, San Francisco General Hospital, UCSF, 1001 Potrero Avenue, San Francisco, CA 94110, USA
Public health debates about providing HIV antiretroviral therapy to impoverished populations have centred on the relationship between adherence and risk of drug resistance. Recent data indicate that each antiretroviral therapeutic class has a unique adherence–resistance relationship. Resistance to single protease inhibitor therapy occurs most frequently at moderate to high levels of adherence, resistance to non-nucleoside reverse transcriptase inhibitor therapy occurs at low to moderate levels of adherence, and resistance to ritonavir-boosted protease inhibitor therapy is most likely to occur at middle ranges of adherence. These dynamic relationships should be considered in balancing the individual and public health benefits of therapy.
Keywords: resource-constrained countries, drug users, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, public health
* Corresponding author. Present address: Box 1372, San Francisco General Hospital, UCSF, 1001 Potrero Avenue, Building 100, Room 301, San Francisco, CA 94110, USA. Tel: +1-415-206-3462; Fax: +1-415-206-4360; E-mail: db{at}epi-center.ucsf.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Maggiolo Efavirenz: a decade of clinical experience in the treatment of HIV J. Antimicrob. Chemother., November 1, 2009; 64(5): 910 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Buendia, B. Cadwallader, and V. DeGruttola A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance Bioinformatics, October 1, 2009; 25(19): 2522 - 2529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shuter Forgiveness of non-adherence to HIV-1 antiretroviral therapy J. Antimicrob. Chemother., April 1, 2008; 61(4): 769 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Nachega, M. Hislop, D. W. Dowdy, R. E. Chaisson, L. Regensberg, and G. Maartens Adherence to Nonnucleoside Reverse Transcriptase Inhibitor Based HIV Therapy and Virologic Outcomes Ann Intern Med, April 17, 2007; 146(8): 564 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Braithwaite, S. Shechter, M. S. Roberts, A. Schaefer, D. R. Bangsberg, P. R. Harrigan, and A. C. Justice Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation J. Antimicrob. Chemother., November 1, 2006; 58(5): 1036 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E K. Hester, H. V Chandler, and K. M Sims Fosamprenavir: Drug Development for Adherence Ann. Pharmacother., July 1, 2006; 40(7): 1301 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.J Smith Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges? Proc R Soc B, March 7, 2006; 273(1586): 617 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Slish, L. M. Catanzaro, O. Okusanya, L. M. Demeter, M. Albrecht, R. Difrancesco, and G. D. Morse Therapeutic Drug Monitoring: Role for a Pharmacist in Multidisciplinary Antiretroviral Management Journal of Pharmacy Practice, August 1, 2005; 18(4): 310 - 321. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Moerman, A. Van Gompel, J. Nimmegeers, and J. Moerman Highly active antiretroviral therapy BMJ, June 11, 2005; 330(7504): 1341 - 1342. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Monie, R. P. Simmons, R. E. Nettles, T. L. Kieffer, Y. Zhou, H. Zhang, S. Karmon, R. Ingersoll, K. Chadwick, H. Zhang, et al. A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients J. Virol., April 15, 2005; 79(8): 5185 - 5202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Green There are no paradoxes of adherence and drug resistance to HIV antiretroviral therapy J. Antimicrob. Chemother., September 1, 2004; 54(3): 694 - 694. [Full Text] [PDF]
|
|